Bio-Rad Laboratories Inc (BIO-B)

Bio-Rad Laboratories' stock saw a 4.5% jump following its Q2 2026 earnings report, with revenue of US$651 million and non-GAAP EPS of US$2.62, broadly flat year-over-year. The company's digital PCR (ddPCR) revenue grew 6% with instrument sales up over 20%, supporting a "bull case" for growth through new platforms and operational tightening. However, flat currency-neutral revenue guidance and concerns about earnings volatility due to pricing pressure and weak funding remain for the "bear case."

Bio-Rad reported a modest sequential improvement in its second-quarter earnings, with a 1.9% year-on-year revenue decline at constant currency and a non-GAAP operating margin of 12.5%. Despite this, management reiterated broad full-year guidance ranges for revenue change and operating margin, indicating continued uncertainty.

Eva Anette Engelhardt, EVP and President, CDG of Bio-Rad Laboratories (NYSE: BIO), had 246 Restricted Stock Units vest on July 25, 2026. To cover tax obligations, 89 shares were withheld at a price of $314.46 per share. After this transaction, she holds 492 remaining RSUs, which vest at a rate of 25% annually over four years.

This article provides a forecast for Bio-Rad Laboratories, Inc. Class A (BUWA) stock, including price targets from analysts and historical performance. It details the company's financials, earnings reports, revenue, net income, and current market capitalization. The article also addresses frequently asked questions about BUWA's stock price, volatility, dividends, and investment recommendations.